Business
Lyramid SPA & MK Cell License Update
Roquefort Therapeutics plc has extended the Longstop Dates for both the Lyramid SPA and the MK Cell Out-License agreements with Pleiades Pharma Ltd to December 31, 2026. This extension is necessary to allow Pleiades sufficient time to complete its ongoing fundraising round with GCC investors, as completion of both the Lyramid subsidiary sale and the MK Cell patent out-licensing are contingent on this fundraising. All other terms of the existing agreements remain unchanged. Disclaimer*
About this update from Coiled Therapeutics Plc
[{"type":"text","content":"\n\n25 March 2026\nRoquefort Therapeutics plc\n(\"Roquefort Therapeutics\" or the \"Company\")\nLyramid SPA & MK Cell License Update\n \nRoquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company, announces it has agreed to extend the Longstop Dates (defined below) in relation to the binding share purchase agreement (\"Lyramid SPA\") for the sale of its wholly owned subsidiary Lyramid Pty Ltd to Pleiades Pharma Ltd (\"Pleiades\"), and the binding agreement in relation to the out-licensing of MK Cell patents to Pleiades (\"MK Cell Out-License\") to 31 December 2026.\n \nAs previously announced, completion of the Lyramid SPA is contingent on Pleaides completing a fundraising round by a certain date (the \"Lyramid SPA Longstop Date\"). The current Lyramid SPA Longstop Date is 31 March 2026. Similarly, in accordance with the terms of the MK Cell Out-License, Pleaides is required to complete a fundraising round by a certain date (the \"MK Cell Longstop Date\"). The current MK Cell Longstop Date is 2 May 2025. \n \nPleiades' fundraising with institutional and sovereign wealth fund investors in the GCC (Gulf Cooperation Council) is continuing, however, the current Lyramid SPA Longstop Date and MK Cell Longstop Date (together the \"Longstop Dates\") do not allow sufficient time for Pleiades to complete its fundraising round and accordingly the parties have agreed to extend the Longstop Dates. All other terms in the Lyramid SPA and MK Cell Out-License remain unchanged.\n \nRegulatory Information\nThis Announcement contains inside information for the purposes of the UK version of the market abuse regulation (EU No. 596/2014) as it forms part of United Kingdom domestic law by virtue of the European Union (Withdrawal) Act 2018 (\"UK MAR\").\n \n-ENDS-\n \nEnquiries:\n\n\n\n\nRoquefort Therapeutics plc\nStephen West (Chairman)\n \n \n\n\n+44 (0)20 3918 8633\n\n\n\n\nSP Angel Corporate Finance LLP (Joint Broker)\nDavid Hignell / Adam Cowl / Devik Mehta (Corporate Finance)\nVadim Alexandre / Rob Rees (Corporate Broking)\n \n\n\n+44 (0)20 3470 0470\n \n\n\n\n\n \nShard Capital Partners LLP (Joint Broker)\nDamon Heath\n \nCPS Capital Group Pty Ltd (Joint Broker)\nJason Peterson / David Valentino\n \n\n\n+44 (0)20 4530 6926\n \n \n+61 (0)8 9223...